doi:10.1093/humupd/dmz019 Outeirino-Iglesias V, Romani-Perez M, Gonzalez-Matias LC, Vigo E, Mallo F
However, the same hormonal action that makes tirzepatide most effective for weight loss often causes significant early side effects, such as nausea and vomiting, during the start of the treatment or during the escalation phase
The concentration of the plasmid is 166 ng/l
On December 15, 2022, the FDA added tirzepatide to its drug shortage list, which allowed compounding pharmacies to legally produce it due to the shortage
The medication is injected subcutaneously into the abdomen, thigh, or upper arm, with rotation of injection sites recommended
this resulted in limited access to treatment for diabetic patients